Core Viewpoint - The launch of Pemafibrate (brand name: Paireda®) by Hoshino Corporation on Alibaba Health marks the first official online availability of this next-generation selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) [1][5]. Group 1: Product Overview - Pemafibrate has been approved by the National Medical Products Administration since April 2025 and is now available to patients through an authorized e-commerce platform [1]. - The drug has been on the market in Japan for nine years and is recognized for its efficacy in lowering triglycerides while ensuring liver and kidney safety [1][5]. Group 2: Clinical Significance - Hypertriglyceridemia is prevalent in China, with a reported incidence rate of 15% to 22.4%, yet treatment and control rates are low at 11.6% and 5.4%, respectively [3]. - Each 1 mmol/L increase in triglyceride levels raises the risk of microvascular events by 35% and the risk of type 2 diabetes by 81% [3]. - Pemafibrate demonstrates a 2500-fold stronger activation effect on PPARα compared to traditional fibrates, with a clinical trial showing a 51.8% reduction in triglycerides at a dosage of 0.4 mg/day [3]. Group 3: Target Population - Pemafibrate is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and those not achieving triglyceride targets while on statins [4][5]. - The drug has received recognition from various authoritative guidelines, including the 2023 Chinese Lipid Management Guidelines and the European Society of Cardiology guidelines, confirming its efficacy and safety [5].

Core Viewpoint - The launch of Pemafibrate (brand name: Pailongda®) on Alibaba Health marks the first official online availability of this selective PPARα modulator in China, providing a new treatment option for patients with hypertriglyceridemia (HTG) [2][5]. Group 1: Product Launch and Significance - Pemafibrate has been approved by the National Medical Products Administration since April 2025 and is now available through an authorized e-commerce platform, enhancing access for patients nationwide [2]. - The drug has been on the market in Japan for nine years and is recognized for its efficacy in lowering triglycerides while ensuring liver and kidney safety [2][6]. Group 2: Clinical Data and Efficacy - Epidemiological data indicates that the prevalence of HTG in China is between 15% and 22.4%, with treatment and control rates at only 11.6% and 5.4%, respectively [5]. - Pemafibrate demonstrates a 51.8% reduction in triglyceride levels at a dosage of 0.4 mg/day, outperforming commonly used medications like fenofibrate [5]. - The drug's unique "Y-shaped" molecular structure allows for a 2500-fold stronger activation of PPARα compared to traditional fibrates, showcasing significant clinical advantages [5]. Group 3: Target Patient Population - Pemafibrate is suitable for adult patients with non-familial hypertriglyceridemia, particularly those with poor dietary control, diabetes, or fatty liver, and can be used alone or in combination with statins [6]. - The drug has received recognition from various authoritative guidelines, including the 2023 Chinese Lipid Management Guidelines, confirming its normative use and effectiveness [6].

Group 1 - The core point of the article is the launch of Pemafibrate, a novel lipid-lowering drug by Japan's Kowa Company, on Meituan's self-operated pharmacy platform, marking its first appearance online [1] - Pemafibrate is the world's first highly selective PPARα modulator, demonstrating over 2500 times stronger activation efficacy compared to the active metabolite of Fenofibrate, thus offering high selectivity, low dosage, and fewer adverse reactions [1] - The drug is expected to be officially approved in China by April 2025 for the treatment of dyslipidemia, with Harbin Yuheng Pharmaceutical acting as its promotional agent, highlighting the significant market interest in its launch [1] Group 2 - Meituan's self-operated pharmacy has over 1300 types of imported original research drugs and boasts a delivery service where over 90% of orders can be delivered on the same or next day [2] - The platform has become a crucial launchpad for new and specialty drugs, indicating its growing importance in the pharmaceutical e-commerce sector [2] - The increasing demand for lipid-lowering medications is underscored by over 12 million users searching for such products on Meituan in the past six months, reflecting a substantial health need in the market [1]